Chinook Therapeutics, Inc. (KDNY)

NASDAQ: KDNY · IEX Real-Time Price · USD
24.54
-0.73 (-2.89%)
Feb 1, 2023, 10:25 AM EST - Market open
-2.89%
Market Cap 1.57B
Revenue (ttm) 56.85M
Net Income (ttm) -117.77M
Shares Out 63.94M
EPS (ttm) -1.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 80,553
Open 25.18
Previous Close 25.27
Day's Range 24.30 - 25.48
52-Week Range 11.81 - 27.44
Beta 0.36
Analysts Buy
Price Target 37.17 (+51.47%)
Earnings Date Mar 16, 2023

About KDNY

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the t... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Stephen Isaacs
Employees 138
Stock Exchange NASDAQ
Ticker Symbol KDNY
Full Company Profile

Financial Performance

In 2021, KDNY's revenue was $51.63 million, an increase of 6142.44% compared to the previous year's $827,000. Losses were -$102.94 million, 26.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for KDNY stock is "Buy." The 12-month stock price forecast is $37.17, which is an increase of 51.47% from the latest price.

Price Target
$37.17
(51.47% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Chinook Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for...

1 month ago - GlobeNewsWire

Chinook Therapeutics to Present at Upcoming Investor Conferences

SEATTLE, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for...

2 months ago - GlobeNewsWire

Chinook Therapeutics (KDNY) Reports Q3 Loss, Tops Revenue Estimates

Chinook (KDNY) delivered earnings and revenue surprises of -33.87% and 614.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Chinook Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

SEATTLE, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for...

2 months ago - GlobeNewsWire

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and CHK-336 Preclinical Efficacy Data at the American Society of Nephrology (ASN) Kidney Week 2022

SEATTLE, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for...

3 months ago - GlobeNewsWire

Chinook Therapeutics Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022

SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for...

3 months ago - GlobeNewsWire

Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the American Society of Nephrology (ASN) Kidney Week 2022

SEATTLE, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for...

3 months ago - GlobeNewsWire

Chinook Therapeutics (KDNY) Reports Q2 Loss, Misses Revenue Estimates

Chinook (KDNY) delivered earnings and revenue surprises of 1.61% and 83.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Chinook Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for...

6 months ago - GlobeNewsWire

Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for...

6 months ago - GlobeNewsWire

7 Cheap Biotech Stocks to Buy Now

Biopharmaceutical companies have been struggling since 2021 and that narrative isn't immediately changing. However, not every firm deserves this fate.

6 months ago - InvestorPlace

Chinook (KDNY) Is a Great Choice for "Trend" Investors, Here's Why

Chinook (KDNY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

6 months ago - Zacks Investment Research

Here's Why Chinook Therapeutics (KDNY) is a Great Momentum Stock to Buy

Does Chinook Therapeutics (KDNY) have what it takes to be a top stock pick for momentum investors? Let's find out.

7 months ago - Zacks Investment Research

Here's Why "Trend" Investors Would Love Betting on Chinook (KDNY)

Chinook (KDNY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

7 months ago - Zacks Investment Research

Chinook (KDNY) Stock Rallies 24.2% in 3 Months: Here's Why

Despite no marketable drugs in its portfolio, Chinook (KDNY) is progressing well with its pipeline. Updated data from a study supports the potential clinical utility of BION-1301 in the IgA nephropath...

7 months ago - Zacks Investment Research

4 Small Stocks to Bet on in an Upbeat Drugs Industry

It is expected that innovation will continue to drive growth in the Medical-Drugs industry in 2022. KDNY, ASRT, VIRX, SLNO may prove to be good additions to one's portfolio.

Other symbols: ASRTSLNOVIRX
7 months ago - Zacks Investment Research

Chinook Therapeutics to Present at the William Blair Biotech Focus Conference 2022

SEATTLE, July 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for...

7 months ago - GlobeNewsWire

Chinook Therapeutics Receives Orphan Drug Designation from European Commission for BION-1301 for Treatment of Primary IgA Nephropathy (IgAN)

SEATTLE, July 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for...

7 months ago - GlobeNewsWire

Here's Why Momentum in Chinook (KDNY) Should Keep going

If you are looking for stocks that are well positioned to maintain their recent uptrend, Chinook (KDNY) could be a great choice. It is one of the several stocks that passed through our "Recent Price S...

7 months ago - Zacks Investment Research

Wall Street Analysts See a 94% Upside in Chinook (KDNY): Can the Stock Really Move This High?

The consensus price target hints at a 93.8% upside potential for Chinook (KDNY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate ...

7 months ago - Zacks Investment Research

Recent Price Trend in Chinook (KDNY) is Your Friend, Here's Why

Chinook (KDNY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our sh...

8 months ago - Zacks Investment Research

Does Chinook (KDNY) Have the Potential to Rally 110% as Wall Street Analysts Expect?

The mean of analysts' price targets for Chinook (KDNY) points to a 109.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst...

8 months ago - Zacks Investment Research

Chinook Therapeutics Announces Pricing of a $105 Million Public Offering

SEATTLE, May 24, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the pricing of its underwritten public offering of 6,428,572 shares of its common stock at a price t...

9 months ago - GlobeNewsWire

Chinook Therapeutics Announces Proposed Public Offering

SEATTLE, May 24, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ...

9 months ago - GlobeNewsWire

Chinook (KDNY) Upgraded to Buy: What Does It Mean for the Stock?

Chinook (KDNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

9 months ago - Zacks Investment Research